DAE HWA Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
DAE HWA Pharmaceutical Co., Ltd.'s Market Cap is ₩2078B. At end of 2025 it was ₩3245B. Ranked #835 of 2,421 in KR market (top 34%), #384 of 1,640 on KOSDAQ (top 23%), #87 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 38%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 207.76B KRW | KR#835/2,421 Sec#87/231 |
| Revenue | 148.75B KRW | KR#1,187/2,421 Sec#71/231 |
| Net Income | 4.86B KRW | KR#1,225/2,421 Sec#83/231 |
| Total Assets | 220.34B KRW | KR#1,244/2,421 Sec#90/231 |
| Net Assets | 85.72B KRW | KR#1,528/2,421 Sec#121/231 |
| Employees | 365 | KR#664/2,421 Sec#58/231 |
| Value | ||
| P/E | 42.73x | KR#1,389/2,421 Sec#87/231 |
| P/B | 2.42x | KR#2,024/2,421 Sec#154/231 |
| PEG | 0.29x | KR#625/2,421 Sec#36/231 |
| P/S | 1.40x | KR#1,599/2,421 Sec#93/231 |
| EV/EBITDA | 55.55x | KR#1,378/2,421 Sec#89/231 |
| FCF Yield | 2.59% | KR#1,017/2,421 Sec#65/231 |
| Profitability | ||
| ROE | 5.67% | KR#1,018/2,421 Sec#70/231 |
| ROA | 2.21% | KR#1,179/2,421 Sec#88/231 |
| Op. Margin | 3.72% | KR#1,134/2,421 Sec#81/231 |
| Revenue Growth | 0.14% | KR#1,523/2,421 Sec#152/231 |
| Earnings Growth | 147.12% | KR#315/2,421 Sec#18/231 |
| Financial Health | ||
| Debt Ratio | 157.03% | KR#1,947/2,421 Sec#210/231 |
| Total Debt | 101.61B KRW | KR#719/2,421 Sec#45/231 |
| FCF | 5.38B KRW | KR#885/2,421 Sec#61/231 |
| Cash | 2.15B KRW | KR#2,240/2,421 Sec#212/231 |
| Current Ratio | 0.56x | KR#2,108/2,421 Sec#201/231 |
| Net Debt/EBITDA | 17.98x | KR#1,353/2,421 Sec#97/231 |
| Dividend | ||
| Div. Yield | 1.35% | KR#1,038/2,421 Sec#56/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -22.12% | KR#1,317/2,421 Sec#93/231 |
| 1M Return | 6.90% | KR#635/2,421 Sec#44/231 |
| From 52W High | -55.18% | KR#1,663/2,421 Sec#126/231 |
| 1Y MDD | -66.22% | KR#1,806/2,421 Sec#150/231 |
| Trading | ||
| Volume | 57,042 shares | KR#1,066/2,421 Sec#104/231 |
| Trading Value | 637.4M KRW | KR#860/2,421 Sec#85/231 |
| Foreign Own. | 0.47% | KR#2,216/2,421 Sec#213/231 |
| Per Share | ||
| EPS | 261 KRW | KR#1,212/2,421 Sec#83/231 |
| BPS | 4,605 KRW | KR#1,550/2,421 Sec#112/231 |
Company Info
Established in 1984 and listed on KOSDAQ in 2003, Daehwa Pharmaceutical is an innovative pharmaceutical company with 5 subsidiaries, including 3 domestic and 2 overseas. It engages in pharmaceutical manufacturing, wholesale, medical information systems, and the manufacturing and sales of pharmaceutical raw materials, cosmetics, and medical devices. The company produces treatments for infectious and digestive diseases at its GMP-certified factories, capturing 65% of the domestic OEM market. Daehwa Pharmaceutical is headquartered in Hoengseong-gun, Gangwon-do.